ClinicalTrials.gg
RecruitingNCT06165341Updated Nov 12, 2026

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

A Phase 3 interventional study of Fazirsiran Injection and Placebo in Alpha1-Antitrypsin Deficiency, sponsored by Takeda. Recruiting at 41 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 12, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in alpha 1-Antitrypsin Deficiency by Takeda — 3 open to participants now, 4 under way, 3 of them phase 3. alpha 1-Antitrypsin Deficiency · Takeda.

Planned enrollment
4th of 13
50 · median 30
Started
2024
with 2 others
Phase 3
5 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in alpha 1-Antitrypsin Deficiency by Takeda, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 in phase 3, and was the 13th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

3 of the 14 studies in alpha 1-Antitrypsin Deficiency by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in alpha 1-Antitrypsin Deficiency by Takeda, or all of them as a file.
02

Study summary

The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver.

People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study.

After their last clinic visits, participants will have two choices:

  1. They can complete this study and return to the clinic 3 and 6 months later so the study doctors can check for side effects; OR
  2. If they meet the rules, they can join another study (called extension or continuation study), in which they will receive fazirsiran every 3 months and will continue to have health checks.
03

Conditions studied

  • Alpha1-Antitrypsin Deficiency
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In the opinion of the investigator, the participant is capable of understanding and fully complying with the protocol requirements and adhering to the protocol schedule.
  • The participant is able to read, understand, and complete the study questionnaires electronically per the investigator's judgment.
  • The participant signs and dates a written Form (ICF). Any required privacy authorization should also be signed before the initiation of any study procedures.
  • The participant, of any sex, is aged 18 to 75 years, inclusive.
  • The participant must have a diagnosis of the protease inhibitor Z mutation (PiZZ) genotype AATD. A diagnosis of PiZZ from source-verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.
  • The participant's liver core samples collected as per protocol requirements.
  • The participant has evidence of METAVIR stage F1 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading from a previous biopsy conducted within 1 year before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.
  • The participant has a pulmonary status that meets the protocol requirements.
  • It must be confirmed that the participant does not have hepatocellular carcinoma (HCC).
  • Any participant who is taking statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or beta-1 selective adrenergic receptor inhibitors must have been receiving a stable dose of these medications for at least 8 weeks before randomization. All attempts are to be made for the participant to continue the same dose of the medication for the duration of study participation.
  • An adult participant must have a (BMI) greater than or equal to (>=) 18 kilogram per meter square (kg/m\^2).
  • The participant has a 12-lead at screening that, in the opinion of the investigator, has no abnormalities that could compromise the participant's safety in this study.
  • The participant is a nonsmoker.
  • If the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled , or low-dose systemic corticosteroids (prednisone less than or equal to [\<=10] milligrams per day [mg/d] or its equivalent), the doses of the participant's medications must have remained unchanged for >=4 weeks before screening.
  • The participant must have suitable venous access for blood sampling.
  • A person of (POCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 before dosing.
  • The participant must use appropriate methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study and for 6 months after the last dose of study medication. The participant must not donate sperm for at least 6 months after the last dose of study medication.

Exclusion criteria

Exclusion criteria:

  • The participant has evidence of >= F2 fibrosis based on liver during the screening period.
  • The participant has a history of liver decompensating events.
  • The participant has a history of varices based on a previous esophagogastroduodenoscopy.
  • The participant has portal vein thrombosis.
  • The participant has undergone a prior trans-jugular portosystemic shunt procedure.
  • The participant has evidence of other forms of chronic liver diseases.
  • The participant has a history of within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of disease and disease-free interval greater than (>) 1 year may be enrolled. Individual cases may be discussed with the medical monitor for guidance.
  • The participant has an abnormal finding of clinical relevance at the screening evaluation and before administration of the first dose of study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results.
  • The participant has any laboratory abnormalities at screening and before the first dose of the study drug that meet protocol parameters.
  • The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.
  • The participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months prior to screening, unless, in the opinion of the investigator, the participant has achieved clinical recovery with pulmonary function returned to baseline. Individual cases may be discussed with the medical monitor for guidance.
  • The participant has a history of frequent pulmonary exacerbations (>=2 moderate or severe exacerbations within 52 weeks before screening).
  • The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be rescreened after the clinical resolution of an exacerbation).
  • The participant is receiving long-term, around-the-clock oxygen supplementation or supplemental oxygen with continuous positive airway pressure (CPAP) or bilevel positive airway pressure for acute respiratory failure. The following conditions are allowable for the participant to enter screening: short-term use of oxygen supplementation (example, for the management of acute [COPD] exacerbation) or CPAP for obstructive sleep apnea.
  • The participant has (HIV) infection as shown by the presence of anti-HIV antibody (seropositive).
  • The participant is seropositive for virus (HBV surface antigen positive and/or HBV core antibody positive without HBV surface antibody at screening) or virus (HCV) (detectable HCV Ribonucleic Acid [RNA] at screening). Cured HCV (positive antibody test without detectable HCV RNA for at least 6 months after treatment) is acceptable.
  • The participant has unstable, poorly controlled, or severe hypertension. Participants may be rescreened once their blood pressure (BP) is successfully controlled.
  • The participant has a history of abnormalities that are considered and would pose an unacceptable risk to the participant if they participate in the study, in the opinion of the investigator. Examples of significant ECG abnormalities include: torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long syndrome or new ST-segment elevation or depression or a new Q wave on ECG.
  • The participant has symptomatic heart failure (per guidelines), unstable angina, myocardial infarction, severe cardiovascular disease ( less than [\<] 20 percent [%]), , or cerebrovascular accident within 6 months before screening.
  • The participant has a history of major surgery within 12 weeks of screening (or longer, at the discretion of the investigator).
  • The participant has a history of more than moderate alcohol consumption within 12 months before the screening visit.
  • The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.
  • The participant has previously been treated with fazirsiran or any other RNA interference (RNAi) for alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).
  • The participant has a history of or allergies with any associated of fazirsiran.
  • The participant has received an agent or device within 30 days, or 5 half-lives, whichever is longer, before the dosing of study medication or is currently participating in an investigational study involving a therapeutic intervention.
  • The participant has donated >=500 milliliter (mL) of blood within 1 month of the administration of study treatment.
  • The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk. The participant has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurologic, psychiatric, gastrointestinal (GI), systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
  • The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 6 months before screening, or is taking chronic anticoagulants.
  • This participant is unable to return for all scheduled study visits.
  • The participant has symptomatic confirmed coronavirus disease 2019 (COVID-19) that, in the opinion of the investigator, does not resolve during screening; however, enrollment may be temporarily delayed at the discretion of the investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation. Individual cases may be discussed with the medical monitor for guidance.
  • The participant is a study site employee involved in the conduct of this study, an immediate family member (example, spouse, parent, child, sibling), is in a dependent relationship with study site employee who is involved in the conduct of this study or may consent under duress.
  • The participant takes or is required to take excluded medications.
  • The participant is pregnant or breastfeeding or intending to become pregnant before participating in this study, during the study, or within 6 months after last dose of the study drug; or the participant is intending to donate ova during such time period.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Fazirsiran 200 mg

    Participants will receive fazirsiran 200 milligrams (mg), injection, subcutaneously on Day 1, at Week 4 and then every 12 weeks (Q12W) for up to Week 100.

    Drug: Fazirsiran Injection

  • Placebo comparator
    Placebo

    Participants will receive fazirsiran matching placebo injection, subcutaneously on Day 1, at Week 4 and Q12W for up to Week 100.

    Drug: Placebo

Interventions

  • DrugFazirsiranStudies of FazirsiranFazirsiran pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fazirsiran will be injected subcutaneously.

    Also known as: TAK-999, ARO-AAT, ADS-001

  • DrugPlacebo

    Fazirsiran matching placebo.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study intervention. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, suspected transmission of any infectious agent, an important medical event. AEs and SAEs including any pulmonary AEs or SAEs indicative of worsening pulmonary condition (example, pulmonary exacerbation, respiratory infection, significant pulmonary function test decline) will be reported.

    Time frame: From start of study drug administration up to end of study (EOS) (Week 124)

  2. Number of Participants With Clinically Significant Change From Baseline in Pulmonary Function Parameters

    Standard pulmonary function parameters will be used to study lung function. Clinical significance of pulmonary function parameters will be determined at the investigator's discretion.

    Time frame: From start of study drug administration up to EOS (Week 124)

  3. Change From Baseline in Whole Lung 15th Percentile Density as Measured by Computed Tomography (CT) Lung Densitometry

    Change from baseline in whole lung 15th percentile density as measured by CT lung densitometry will be assessed.

    Time frame: Baseline up to Week 100

  4. Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs include body temperature, respiratory rate, blood pressure (systolic and diastolic), pulse (beats per minute) and pulse oximetry. Clinical significance of vital signs will be determined at the investigator's discretion.

    Time frame: From start of study drug administration up to EOS (Week 124)

  5. Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    12-lead ECG will be evaluated. Any clinically significant change in ECG assessments will be determined at the investigator's discretion.

    Time frame: From start of study drug administration up to EOS (Week 124)

  6. Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

    Laboratory parameters assessments include hematology, biochemistry including liver tests, coagulation, and urinalysis. Clinical significance of laboratory parameters will be determined at the investigator's discretion.

    Time frame: From start of study drug administration up to EOS (Week 124)

Secondary outcomes

  1. Change From Baseline in Serum Z-AAT Protein Over Time to Week 106

    Change From Baseline in Serum Z-AAT Protein will be assessed.

    Time frame: Baseline up to Week 106

  2. Percent Change From Baseline in Intrahepatic Liver Z-AAT Protein at Week 106

    Percent change from baseline in intrahepatic liver Z-AAT protein will be assessed.

    Time frame: Baseline up to Week 106

  3. Change From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 106

    Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining in liver biopsy will be assessed.

    Time frame: Baseline up to Week 106

  4. Number of Participants with No Change or Decrease From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by PAS+D Staining at Week 106

    Number of participants with no change or decrease from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining will be reported.

    Time frame: Baseline up to Week 106

  5. Change From Baseline in Intrahepatic Portal Inflammation Score in Liver Biopsy at Week 106

    Change in portal inflammation score in liver biopsy is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation.

    Time frame: Baseline up to Week 106

  6. Number of Participants with No Change or Decrease From Baseline in Intrahepatic Portal Inflammation Score at Week 106

    No Change or decrease in portal inflammation score is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation. Number of Participants with no change or decrease from baseline in intrahepatic portal inflammation score will be reported.

    Time frame: Baseline up to Week 106

  7. Number of Participants With No Change or Decrease From Baseline in Histologic Fibrosis Score (Meta-analysis of Histological Data in Viral Hepatitis [METAVIR] Staging) at Week 106

    No change or decrease in histologic fibrosis (METAVIR staging) will be assessed using a fibrosis score of F0-F4, where higher scores mean a worse result. Number of participants with no change or decrease from baseline in histologic fibrosis score (by \[METAVIR\] staging) at Week 106 will be reported.

    Time frame: Baseline up to Week 106

  8. Change From Baseline in Vibration-Controlled Transient Elastography (VCTE)-Derived Liver Stiffness

    Change from baseline in VCTE-derived liver stiffness will be assessed.

    Time frame: Baseline up to Week 106

  9. Change From Baseline in Markers of Liver Injury

    Change from baseline in marker (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], glutamyl transferase \[GGT\]) of liver injury will be assessed.

    Time frame: Baseline up to Week 106

07

Study locations

40 of 41 sites recruiting
  • St Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013-4224, United States
    Recruiting
    • Site Contact · Contact602-274-7195
    • Justin Reynolds · Principal investigator
  • Mayo Clinic - PPDS
    Phoenix, Arizona 85054-4502, United States
    Recruiting
    • Site Contact · Contactvargas.hugo@mayo.edu · 480-301-6990
    • Hugo Vargas · Principal investigator
  • University of Arizona Thomas D. Boyer Liver Institute
    Tucson, Arizona 85724-0001, United States
    Recruiting
  • University of California San Diego
    La Jolla, California 92037-1337, United States
    Recruiting
  • UCLA Pulmonary and Critical Care
    Los Angeles, California 90095-3075, United States
    Recruiting
    • Site Contact · Contact310-825-8061
    • Igor Barjaktarevic · Principal investigator
  • University of California Benioff Children's Hospital
    San Francisco, California 94143-2203, United States
    Recruiting
    • Site Contact · ContactPROSENTH@ucsf.edu · 415-476-5892
    • Philip Rosenthal · Principal investigator
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
    Recruiting
    • Site Contact · Contact719-636-1201
    • Bhaktasharan Patel · Principal investigator
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
    Recruiting
  • Indiana University School of Medicine-Indianapolis
    Indianapolis, Indiana 46202-2266, United States
    Recruiting
    • Site Contact · Contact317-278-4607
    • Raj Vuppalanchi · Principal investigator
  • University Of Iowa Hospitals And Clinics
    Iowa City, Iowa 52242-1009, United States
    Recruiting
  • Boston Medical Center
    Boston, Massachusetts 02118-2335, United States
    Recruiting
  • University of Michigan Hospital - 1500 E Medical Center Dr
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Site Contact · Contact734-232-3741
    • Robert Fontana · Principal investigator
  • Henry Ford Health System
    Novi, Michigan 48377-3600, United States
    Recruiting
    • Site Contact · Contactsgordon3@hfhs.org · 248-344-6688
    • Stuart Gordon · Principal investigator
  • Mayo Clinic PPDS
    Rochester, Minnesota 55905, United States
    Recruiting
    • Site Contact · Contact507-284-0141
    • Harmeet Malhi · Principal investigator
  • NYU Langone Medical Center
    New York, New York 10016-6402, United States
    Recruiting
  • Columbia University Irving Medical Center
    New York, New York 10032-3722, United States
    Recruiting
    • Monica Goldklang · Principal investigator
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106-1716, United States
    Recruiting
    • Site Contact · Contact216-983-0879
    • Seth Sclair · Principal investigator
  • Penn State Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033-2360, United States
    Recruiting
  • Texas Liver Institute American Research Corporation
    San Antonio, Texas 78215, United States
    Recruiting
    • Site Contact · Contactlawitz@txliver.com · 210-253-3426
    • Eric Lawitz · Principal investigator
  • Bon Secours St. Mary's Hospital
    Newport, Virginia 23602-4414, United States
    Recruiting
  • LKH-Universitätsklinikum Graz
    Graz, 8036, Austria
    Recruiting
  • KABEG - Klinikum Klagenfurt Am Wörthersee
    Klagenfurt, 9020, Austria
    Recruiting
    • Markus Peck-Radosavljevic · Principal investigator
  • UZ Antwerpen
    Antwerp, 2650, Belgium
    Recruiting
    • Site Contact · Contactsven.francque@uza.be · +3238213323
    • Sven Francque · Principal investigator
  • UZ Leuven
    Leuven, 3000, Belgium
    Recruiting
  • Inspiration Research Limited
    Toronto, Ontario M5T 3A9, Canada
    Recruiting
    • Site Contact · Contact(416) 944-9602
    • Kenneth Chapman · Principal investigator
  • Hôpital de La Croix Rousse
    Lyon, 69317, France
    Recruiting
  • Hopital PONTCHAILLOU CHU de Rennes
    Rennes, 35000, France
    Recruiting
  • Hôpital Paul Brousse
    Val-de-Marne, 94800, France
    Recruiting
  • Universitätsklinikum der RWTH Aachen
    Aachen, 52074, Germany
    Recruiting
  • Charité - Campus Virchow-Klinikum
    Berlin, 13353, Germany
    Recruiting
  • Hannover Medical School
    Hanover, 30625, Germany
    Recruiting
    • Site Contact · Contact+495115322730
    • Heiner Wedemeyer · Principal investigator
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
    Recruiting
    • Site Contact · Contact+4970712977661
    • Christoph Berg · Principal investigator
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
    Recruiting
    • Site Contact · Contact+390382503777
    • Angelo Corsico · Principal investigator
  • ID Clinic Arkadiusz Pisula
    Mysłowice, 41-400, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • CCA Hospital Braga
    Braga, 4710-243, Portugal
    Recruiting
    • Carla Rolanda · Principal investigator
  • Hospital Dr. Nélio Mendonça
    Funchal, 9000-168, Portugal
    Recruiting
    • Site Contact · Contact(351) 291-7056 x00
    • Vitor Pereira · Principal investigator
  • Centro Hospitalar de Universitário de Santo António E.P.E
    Porto, 4099-001, Portugal
    Recruiting
    • Site Contact · Contact+351918000000
    • Luís Maia · Principal investigator
  • Hospital Universitario Virgen del Rocio - PPDS
    Seville, 41018, Spain
    Recruiting
    • Site Contact · Contactmromerogomez@us.es · +34955012065
    • Manuel Romero Gómez · Principal investigator
  • Karolinska Universitetssjukhuset Huddinge
    Huddinge, 14186, Sweden
    Recruiting
    • Site Contact · Contact+46858580000
    • Staffan Wahlin · Principal investigator
  • Universitätsspital Bern
    Bern, 3010, Switzerland
    Recruiting
    • Site Contact · Contact+41442663568
    • Guido Stirnimann · Principal investigator
  • King's College Hospital
    London, SE5 9RS, United Kingdom
    Recruiting
    • Site Contact · Contact+442032993506
    • Aftab Ala · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Aug 2028, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 11, 2023
StartActual
Mar 1, 2024
Primary completionEst.
Aug 26, 2028
CompletionEst.
Aug 26, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited; 4 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAn adult participant must have a body mass index (BMI) betweengreater than or equal to (>=) 18 and 39 kilogram per meter square (kg/m\^2), inclusive.
  • EditedIf the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone less than or equal to [<=10] milligrams per day [mg/d] or its equivalent), the doses of the participant's medications must have remained unchanged for greater than or equal to (>=) 4 weeks before screening.
Exclusion criteria
  • EditedThe participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of metastatic disease and disease-free interval greater than (>) 1 year may be enrolled after approval by. Individual cases may be discussed with the medical monitor for guidance.
  • EditedThe participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months beforeprior to screening, unless, in the opinion of the investigator, the participant has achieved clinical recovery with pulmonary function returned to baseline. The participantIndividual cases may be screened earlier based on principal investigator (PI) assessment of clinical recovery and return to baseline pulmonary function in discussiondiscussed with the medical monitor for guidance.
  • EditedThe participant has a history of ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if they participate in the study, in the opinion of the investigator. Examples of significant ECG abnormalities include: torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long QT syndrome or new ST-segment elevation or depression or a new Q wave on ECG. Participants with a history of atrial arrhythmias should be discussed with the medical monitor.
  • EditedThe participant has known or suspectedsymptomatic confirmed coronavirus disease 2019 (COVID-19) that, in the opinion of the sponsor and investigator, does not resolve during screening; however, enrollment may be temporarily delayed at the discretion of the investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation. Enrollment of participants who fail inclusion due to COVID-19 infectionIndividual cases may be temporarily delayed atdiscussed with the discretion of the sponsor and investigatormedical monitor for guidance. If the participant has a positive polymerase chain reaction (PCR) with no other evidence of infection, a retest may be allowed; however, to enroll in the study the participant must have a negative PCR.
Nov 12, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs)From start of study drug administration up to End of study (EOS) (Week 124) → From start of study drug administration up to end of study (EOS) (Week 124)
Nov 12, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedNumber of Participants with No Change or Decrease From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by PAS+D stainingStaining at Week 106Time frame: Baseline up to Week 106
  • EditedNumber of Participants With No Change or Decrease From Baseline in Histologic Fibrosis Score (Meta-analysis of Histological Data in Viral Hepatitis [METAVIR] Staging ) at Week 106Time frame: Baseline up to Week 106
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Eligibility 2 inclusion criteria edited; 4 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAn adult participant must have a body mass index (BMI) betweengreater than or equal to (>=) 18 and 39 kilogram per meter square (kg/m\^2), inclusive.
    • EditedIf the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone less than or equal to [<=10] milligrams per day [mg/d] or its equivalent), the doses of the participant's medications must have remained unchanged for greater than or equal to (>=) 4 weeks before screening.
    Exclusion criteria
    • EditedThe participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of metastatic disease and disease-free interval greater than (>) 1 year may be enrolled after approval by. Individual cases may be discussed with the medical monitor for guidance.
    • EditedThe participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months beforeprior to screening, unless, in the opinion of the investigator, the participant has achieved clinical recovery with pulmonary function returned to baseline. The participantIndividual cases may be screened earlier based on principal investigator (PI) assessment of clinical recovery and return to baseline pulmonary function in discussiondiscussed with the medical monitor for guidance.
    • EditedThe participant has a history of ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if they participate in the study, in the opinion of the investigator. Examples of significant ECG abnormalities include: torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long QT syndrome or new ST-segment elevation or depression or a new Q wave on ECG. Participants with a history of atrial arrhythmias should be discussed with the medical monitor.
    • EditedThe participant has known or suspectedsymptomatic confirmed coronavirus disease 2019 (COVID-19) that, in the opinion of the sponsor and investigator, does not resolve during screening; however, enrollment may be temporarily delayed at the discretion of the investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation. Enrollment of participants who fail inclusion due to COVID-19 infectionIndividual cases may be temporarily delayed atdiscussed with the discretion of the sponsor and investigatormedical monitor for guidance. If the participant has a positive polymerase chain reaction (PCR) with no other evidence of infection, a retest may be allowed; however, to enroll in the study the participant must have a negative PCR.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs)From start of study drug administration up to End of study (EOS) (Week 124) → From start of study drug administration up to end of study (EOS) (Week 124)
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber of Participants with No Change or Decrease From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by PAS+D stainingStaining at Week 106Time frame: Baseline up to Week 106
    • EditedNumber of Participants With No Change or Decrease From Baseline in Histologic Fibrosis Score (Meta-analysis of Histological Data in Viral Hepatitis [METAVIR] Staging ) at Week 106Time frame: Baseline up to Week 106
    + 5 other changes: identifiers, verification date, description, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06165341
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 11, 2023
Start date
Mar 1, 2024
Primary completion
Aug 26, 2028 (estimated)
Completion
Aug 26, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazirsiran

Start the discussion